Corporate
Dec. 5, 2013
Corporate attorneys unfazed by spate of biotech IPO postponements
The biotechnology industry's stampede toward public equity markets hit a bit of a stumbling block last month after a spate of companies in the sector decided to put the brakes on their initial public offerings.
Daily Journal Staff Writer
The biotechnology industry's stampede toward public equity markets recently hit a stumbling block after a spate of companies in the sector decided to put the brakes on initial public offerings last month. But industry analysts and attorneys are convinced that the hot streak isn't over yet.
At least six biotechnology and life sciences postponed their plans to go public in Novem...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In